2017 Fiscal Year Final Research Report
Development of biomarkers for stage II and III colorectal cancer
| Project/Area Number |
15K10143
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Fukushima Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
岡山 洋和 福島県立医科大学, 医学部, 助教 (20583397)
坂本 渉 福島県立医科大学, 医学部, 助教 (40622337)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | 大腸癌 / バイオマーカー |
|---|
| Outline of Final Research Achievements |
Despite the standard treatment with curative surgery and adjuvant chemotherapy, approximately 15-30% of patients with stage II and III colorectal cancer (CRC) will experience disease relapse. We attempted to develop prognostic and predictive biomarkers for postoperative stage II and III CRC that can identify patients with high-risk of recurrence or cancer-death. Using multiple independent cohorts of stage II and III CRC based on microarray, RNA-sequence and immunohistochemistry, we identified several genes that were significantly associated with relapse after surgery. We found that genes and protein expressed by cancer stroma were significantly associated with relapse-free survival in multiple datasets, particularly in stage II colon cancer. Also, some genes were found to be associated with cancer-specific survival in stage III CRC. Collectively, we identified several candidates for the biomarker development for stage II and III CRC, and our finding warrants further investigations.
|
| Free Research Field |
大腸癌
|
